Effect of insulin-like growth factor system on luteinising angiogenesis.

Nwachukwu CU, Robinson RS, Woad KJ

Reproduction & fertility21 Apr 2023Cited by 3 (Europe PMC)

PMID37052337PMCIDPMC10160534DOI10.1530/raf-22-0057PepBankPUB-37052337

Summary

Preovulatory follicle growth and the luteal transition requires intense angiogenesis. This enables progesterone production to increase sufficiently to support a pregnancy. Inadequate follicular or luteal vascularisation can lead to reduced ovarian function and thus compromise fertility. Insulin-like growth factor 1 (IGF1) and IGF2 regulate multiple ovarian processes and are key links between an animal's reproductive and metabolic status. This study investigated the role that the IGF system plays in regulating luteinising follicular endothelial cell (EC) networks and progesterone production in vitro. Bovine luteinising follicular angiogenesis cultures were treated with 1) LR3-IGF1 (10 or 100ng/ml) under basal and angiogenic-stimulated conditions or 2) IGF1 receptor inhibitor (picropodophyllin (PPP); 1µM) in the presence or absence of LR3-IGF1, IGF2, or combined LR3-IGF1+IGF2 (10ng/ml). EC networks were quantified by von Willebrand factor immunohistochemistry. Progesterone production was analysed by ELISA and cell proliferation was determined by MTT assay. LR3-IGF1 had limited effects on EC growth parameters, whilst PPP (p<0.001) markedly reduced EC growth parameters (by 60-70%). Cell proliferation was slightly increased (by 3-5%) by LR3-IGF1 (p<0.001). LR3-IGF1 had variable effects on progesterone production, whilst PPP reduced progesterone concentration (p<0.001) with or without LR3-IGF1 or IGF2 alone or in combination. IGF1 was detected in cell conditioned media and was increased by LH (50ng/ml) (p<0.001). In conclusion, exogenous IGF1 and IGF2 had minimal effects on luteinising follicular angiogenesis and progesterone production, but the inhibitory effect of the IGFR1 inhibitor (PPP) suggests that IGF1 receptor signalling is critical for the development of EC networks and progesterone production in luteinising follicular cells.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

01LabIn vitro (cells)Efficacy outcome
In bovine luteinising follicular angiogenesis cultures, LR3-IGF1 had limited effects on endothelial cell growth parameters.
In plain wordsIn cow ovarian cell cultures, LR3-IGF1 had little effect on blood vessel cell growth.
Peptide
IGF-1 LR3
Outcome
No significant changeEndothelial cell network growth parameters
Study
bovinen: not reported in source
Luteinising follicular angiogenesis cultures
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
10 or 100 ng/mlAs given in this study (bovine).
Source sentences
Summary
LR3-IGF1 had limited effects on EC growth parameters, whilst PPP (p<0.001) markedly reduced EC growth parameters (by 60-70%).
1 context sentence(design, population, supporting numbers)
Summary · context
Bovine luteinising follicular angiogenesis cultures were treated with 1) LR3-IGF1 (10 or 100ng/ml) under basal and angiogenic-stimulated conditions or 2) IGF1 receptor inhibitor (picropodophyllin (PPP); 1µM) in the presence or absence of LR3-IGF1, IGF2, or combined LR3-IGF1+IGF2 (10ng/ml).
Show in the study text Report a problemFND-3705233701
02LabIn vitro (cells)Efficacy outcome
In bovine luteinising follicular angiogenesis cultures, LR3-IGF1 slightly increased cell proliferation.
In plain wordsIn cow ovarian cell cultures, LR3-IGF1 slightly increased cell proliferation.
Peptide
IGF-1 LR3
Outcome
IncreaseCell proliferation (MTT assay)
Study
bovinen: not reported in source
Luteinising follicular angiogenesis cultures
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
10 or 100 ng/mlAs given in this study (bovine).
Measurements
Increase in cell proliferation
3 to 5%
LR3-IGF1
Source sentences
Summary
Cell proliferation was slightly increased (by 3-5%) by LR3-IGF1 (p<0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
Bovine luteinising follicular angiogenesis cultures were treated with 1) LR3-IGF1 (10 or 100ng/ml) under basal and angiogenic-stimulated conditions or 2) IGF1 receptor inhibitor (picropodophyllin (PPP); 1µM) in the presence or absence of LR3-IGF1, IGF2, or combined LR3-IGF1+IGF2 (10ng/ml).
Show in the study text Report a problemFND-3705233702
03LabIn vitro (cells)Efficacy outcome
In bovine luteinising follicular angiogenesis cultures, LR3-IGF1 had variable effects on progesterone production.
In plain wordsIn cow ovarian cell cultures, LR3-IGF1 had variable effects on progesterone production.
Peptide
IGF-1 LR3
Outcome
MixedProgesterone production
Study
bovinen: not reported in source
Luteinising follicular angiogenesis cultures
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
10 or 100 ng/mlAs given in this study (bovine).
Source sentences
Summary
LR3-IGF1 had variable effects on progesterone production, whilst PPP reduced progesterone concentration (p<0.001) with or without LR3-IGF1 or IGF2 alone or in combination.
1 context sentence(design, population, supporting numbers)
Summary · context
Bovine luteinising follicular angiogenesis cultures were treated with 1) LR3-IGF1 (10 or 100ng/ml) under basal and angiogenic-stimulated conditions or 2) IGF1 receptor inhibitor (picropodophyllin (PPP); 1µM) in the presence or absence of LR3-IGF1, IGF2, or combined LR3-IGF1+IGF2 (10ng/ml).
Show in the study text Report a problemFND-3705233703

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 21:44 UTC
Study results updated
Version 1
13 Oct 2026, 16:31 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.